City of Hope Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, City of Hope Medical Center sits in the top decile of US sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count).

582 total trials 167 currently recruiting 217 completed early-phase tilt top decile by trial count

City of Hope Medical Center: 582 sponsored US clinical trials, 167 recruiting.

City of Hope Medical Center sponsors 582 registered US clinical trials on ClinicalTrials.gov, 167 of them currently recruiting, and 217 completed. 9 of these trials are in Phase 3-4 (later-stage) and 382 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 22 trials.

Top-decile sponsor footprint

City of Hope Medical Center ranks in the top decile of sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

217 of 245 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

582 total, page 10 of 12

COMPLETED Phase 2

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

NCT01267812

COMPLETED Phase 1

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

NCT01191684

COMPLETED NA

Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff

NCT01432431

COMPLETED Phase 1

Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01205022

TERMINATED NA

Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer

NCT01254734

TERMINATED Phase 2

Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

NCT01320683

COMPLETED Phase 1

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

NCT01163357

COMPLETED Phase 2

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

NCT01157091

COMPLETED Phase 1

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

NCT01234740

COMPLETED

Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer

NCT01277562

COMPLETED Phase 1

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

NCT01172964

TERMINATED Phase 2

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

NCT01159067

COMPLETED Phase 1

Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

NCT01084057

COMPLETED Phase 1

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

NCT01082926

TERMINATED Phase 1

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT01116154

COMPLETED Phase 1

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

NCT01074060

TERMINATED Early Phase 1

Gene Transfer for HIV Using Autologous T Cells

NCT01153646

COMPLETED Phase 1

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

NCT01135472

TERMINATED NA

Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

NCT01050075

COMPLETED Phase 1

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT01041443

COMPLETED NA

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

NCT01051076

COMPLETED

MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer

NCT01231386

COMPLETED NA

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery

NCT00823667

COMPLETED NA

Palliative Care Teaching Sessions for Family Caregivers of Patients With Non-Small Cell Lung Cancer

NCT00827333

COMPLETED

Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

NCT01176253

COMPLETED Phase 1

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

NCT00962507

COMPLETED

Assessment of Older Adults With Cancer: Feasibility of Computer Survey Methodology

NCT00977834

TERMINATED Phase 1

Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer

NCT00932035

COMPLETED Phase 1

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

NCT00873275

COMPLETED Phase 1

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

NCT00779168

COMPLETED Phase 1

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00825201

COMPLETED Phase 2

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

NCT00810797

COMPLETED

Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer

NCT00950144

COMPLETED Phase 1

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00857025

COMPLETED NA

Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer

NCT00937989

COMPLETED Phase 1

Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer

NCT00828074

TERMINATED NA

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

NCT00952185

TERMINATED Phase 1

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

NCT00800150

COMPLETED Phase 1

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

NCT00708604

COMPLETED NA

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732

COMPLETED

Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

NCT01048918

TERMINATED Phase 1

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

NCT00788125

COMPLETED Phase 1

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00816283

COMPLETED Phase 1

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452

COMPLETED NA

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

NCT00748267

COMPLETED NA

Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors

NCT00903474

COMPLETED Phase 2

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

NCT00720876

COMPLETED NA

Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer

NCT00902733

COMPLETED

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

NCT00806650

COMPLETED NA

Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer

NCT00900679

← Previous Page 10 of 12 Next →

What is open in the City of Hope Medical Center pipeline

167 recruiting of 582 indexed (29% open); 217 completed (37%).

Phase mix: 9 late (III/IV) vs 382 early (I/II) (early-phase heavy).

Top condition: Acute Myeloid Leukemia (22 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

City of Hope Medical Center: open-pipeline peers nationwide

Peers matched on 582 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

City of Hope Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%10%20%30%40% Total trials Recruiting share City of Hope Medical CenterBayerJanssen Research & DevelopmentChildren's Hospital Medical Center, CincinnatiNational Institute of Neurological Disorders and Stroke (NINDS)Methodist Health System89bioAlabama Physical Therapy & AcupunctureAlloSource
City of Hope Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

City of Hope Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 582 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

What to do with this City of Hope Medical Center page

582 registered trials is a research-attention snapshot, not an endorsement of City of Hope Medical Center or any single study.

  • 167 of City of Hope Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Myeloid Leukemia is the condition City of Hope Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. City of Hope Medical Center pipeline card: 582 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.